Abstract：Objective: To predict the active components and targets of Fici Hirtae Radix in the treatment of Myasthenia Gravis ( MG )using network pharmacology and molecular docking technology, and to explore its potential mechanism. Methods: The intersection targets between the action targets of Fici Hirtae Radix and the disease targets of MG were obtained through TCMSP, SwissADME, OMIM, GeneCards and other databases, and the interactions between the targets were resolved and PPI network diagrams were constructed using the STRING database platform. Active ingredient-disease target network analysis was conducted using Cytoscape 3.9.0 software, based on which functional enrichment analysis of GO and KEGG genes was performed using David's database. After screening the key active ingredients and target genes, the active ingredients were molecularly docked to the important targets using Autodock vina and PyMol software to verify the binding activity. Results: Eight effective active components with targets were screened from Fici Hirtae Radix, and eight possible protein targets of TNF, IL6, EGFR and IL1 B in the treatment of MG were predicted. By mediating TNF, Toll-like cell receptor, PI3K-Akt, MAPK and other signaling pathways, anti-inflammatory and improving their immune ability were produced, so as to achieve the occurrence and progress of myasthenia gravis, and the activity between components and targets was preliminarily verified. Conclusion: The characteristics of multi-component, multi-target and multi-pathway in the treatment of MG were revealed by network pharmacology and molecular docking technology, and the possible targets and signal transduction mechanisms of Fici Hirtae Radix in the treatment of myasthenia gravis were explored.
张瀚林, 余洁英, 田恩伟. 基于网络药理学和分子对接探究五指毛桃治疗重症肌无力的作用机制[J]. 河北医学, 2023, 29(2): 242-249.
ZHANG Hanlin, YU Jieying, TIAN Enwei. Study on the Pharmacological Mechanism of Fici Hirtae Radix in Treating Myasthenia Gravis based on Network Pharmacology and Molecular Docking. HeBei Med, 2023, 29(2): 242-249.
[1] 黄嵘.重症肌无力的发病机理和治疗的研究进展(综述) // 中华医学会第十三次全国神经病学学术会议论文汇编[M].2010.362-363. [2] Hehir M K,Silvestri N J.Generalized myasthenia gravis[J].Neurol Clin,2018,36(2):253-260 [3] Koneczny I,Herbst A.Myasthenia gravis:pathogenic effects of autoantibodies on neuromuscular architecture[J].Cells-Basel,2019,8(7):671-672. [4] 刘璇.基于关联规则的重症肌无力中药用药规律研究[D].山东:山东中医药大学,2017. [5] 阳涛,周欣欣,刘小斌.邓铁涛教授函诊治疗重症肌无力用药特点浅析[J].新中医,2011,43(4):134-135. [6] 童妙然,杨晓军,陈楚纯,等.邓中光治疗重症肌无力处方用药分析[J].广州中医药大学学报,2018,35(2):350-353. [7] 钟小清,徐鸿华.五指毛桃的品种考证[J].中药材,2000,23(6):361-362. [8] 陈健,陈启龙.网络药理学在中医药研究中的现状及思考[J].上海中医药大学学报,2021,35(5):1-6. [9] 龚普阳,郭瑜婕,李晓朋,等.基于网络药理学与分子对接技术的金花清感颗粒防治新型冠状病毒肺炎的潜在药效物质研究[J].中草药,2020,51(7):1685-1693. [10] 钟斯然,李宝铜,张帆,等.中药对重症肌无力的作用及机制实验研究进展[J].亚太传统医药,2020,16(3):182-186. [11] 马纳,李亚静,范吉平.金合欢素药理研究进展[J].中国现代应用药学,2018,35(10):1591-1595. [12] 于倩,巫冠中.木犀草素抗炎机制的研究进展[J].药学研究,2019,38(2):108-111. [13] Fan S Y,Zeng H W,Pei Y H,et al.The anti-inflammatory activities of an extract and compounds isolated from platycladus orientalis (Linnaeus) franco in vitro and ex vivo[J].Journal of Ethnopharmacology,2012,141(2):647-652. [14] 赵宁,董倩,付晓幸,等.Acacetin blocks Kv1.3 channels and inhibits human T cell activation // 中国生理学会第24届全国会员代表大会暨生理学学术大会论文汇编[M].2014.273-274. [15] E2 receptor in hepatic is chemia/reperfusion injury in mice.[J].Hepatology,2010,42(3):608-617. [16] Wetzker R,Rommel C.Phosphoinositide 3-kinases as targets for therapeutic intervention[J].Current Pharmaceutical Biotechnology,2004,10(16):1915-1922. [17] 钟斯然,李宝铜,张帆,等.中药对重症肌无力的作用及机制实验研究进展[J].亚太传统医药,2020,16(3):182-186.
2023, Vol. 29 
冀公网安备13080202000677号